Spectrum of EGFR Gene Copy Number Changes and KRAS Gene Mutation Status in Korean Triple Negative Breast Cancer Patients by 源��쑄�젙 et al.
Spectrum of EGFR Gene Copy Number Changes and
KRAS Gene Mutation Status in Korean Triple Negative
Breast Cancer Patients
Yoonjung Kim1, Juwon Kim2, Hy-De Lee3, Joon Jeong3, Woochang Lee4, Kyung-A Lee1*
1Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea, 2Department of Laboratory Medicine, Yonsei University Wonju
College of Medicine, Wonju, Republic of Korea, 3Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea, 4Department of Laboratory
Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Republic of Korea
Abstract
Anti-epidermal growth factor receptor (EGFR) therapy has been tried in triple negative breast cancer (TNBC) patients
without evaluation of molecular and clinical predictors in several randomized clinical studies. Only fewer than 20% of
metastatic TNBCs showed response to anti-EGFR therapy. In order to increase the overall response rate, first step would be
to classify TNBC into good or poor responders according to oncogenic mutation profiles. This study provides the molecular
characteristics of TNBCs including EGFR gene copy number changes and mutation status of EGFR and KRAS gene in Korean
TNBC patients. Mutation analysis for EGFR, KRAS, BRAF and TP53 from a total of 105 TNBC tissue samples was performed by
direct sequencing, peptide nucleic acid-mediated PCR clamping method and real-time PCR. Copy number changes of EGFR
gene were evaluated using multiplex ligation-dependent probe amplification. Out of all 105 TNBCs, 15.2% (16/105) showed
EGFR copy number changes. Among them, increased or decreased EGFR copy number was detected in 13 (5 single copy
gain, 2 amplification and 4 high-copy number amplification) and 3 cases (3 hemizygous deletion), respectively. The
mutation frequencies of KRAS, EGFR and TP53 gene were 1.9% (G12V and G12D), 1.0% (exon 19 del) and 31.4%, respectively.
There was no BRAF V600E mutation found. Future studies are needed to evaluate the clinical outcomes of TNBC patients
who undergo anti-EGFR therapy according to the genetic status of EGFR.
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Introduction
Triple-negative breast cancers (TNBCs) are tumors, nominally
classified as a diagnosis of exclusion, that do not express clinically
significant levels of the estrogen receptor (ER), progesterone
receptor (PgR) and epidermal growth factor receptor 2 (Her-2)
over-expression or gene amplification [1]. TNBCs account for 10–
24% of all invasive breast cancers with a strong predilection for
young women, but the frequency varies by race and in some racial
groups reaches a frequency of up to 55% [2–6]. Hormonal
therapies and HER2-targeted agents are not effective in these
breast tumors, which tend to exhibit aggressive, metastatic
behavior and have a worse prognosis than hormone receptor-
positive, luminal subtypes [1,7,8]. In primary non–small cell lung
cancer that harbors EGFR mutations, multiple randomized clinical
trials comparing first-line chemotherapy to EGFR tyrosine kinase
inhibitors (TKIs) have been performed and uniformly demon-
strated the superiority of EGFR-TKIs [9–12]. In addition, patients
suffering from recurrent glioblastoma with EGFR amplification
and those lacking EGFRvIII expression have been treated with the
EGFR-targeted monoclonal antibody cetuximab with a signifi-
cantly superior progression-free and overall survival [13].
Approximately 20% of metastatic TNBCs showed response to
anti-EGFR therapy in randomized clinical trials [2,14]. Recent
studies have shown no mutations in several target genes associated
with the receptor tyrosine kinase/RAS/MAPK pathway, includ-
ing EGFR, KRAS and BRAF, in the absence of HER2 gene
amplification [15–17]. However, in Asians, EGFR mutations and
copy number changes of the EGFR gene were detected in up to
11.4% [17,18] and 21% of TNBCs [19], respectively. Anti-EGFR
therapies are still an attractive treatment modality according to the
genetic profiles of TNBCs [18–20]. Thus, it would be beneficial to
evaluate mutations and copy number changes of EGFR in TNBC
patients before treating with anti-EGFR drugs, which in turn
would improve the response rates compared to previous data.
Furthermore, a deliberate and clinically applicable method is also
needed to evaluate EGFR mutations and copy number changes as
a molecular predictor for the patients. Here, we report the
mutation status of EGFR, KRAS and BRAF, and the frequency of
EGFR copy number changes in Korean patients with TNBCs.
Materials and Methods
Subject selection
We obtained a total of 105 tissue samples from TNBC patients
at the time of surgery. Triple negative status (negative estrogen
receptor (ER), progesterone receptor (PgR) and c-erbB2) of the
tumors was confirmed by immunohistochemical (IHC) staining.
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Briefly, all IHC staining was performed using formalin-fixed,
paraffin-embedded tissue sections. After deparaffinisation/rehy-
dration and antigen retrieval, paraffin sections were incubated
with primary antibodies against ER (1:50 dilution; Dinona, Seoul,
Korea), PR (1:100 dilution; Dinona) and Her2/neu (1:250
dilution; Dako, Glostrup, Denmark). ER and PR IHC signal
was evaluated using the Allred score [21]. A score of 0 to 2 was
considered negative and a score of 3 to 8 was regarded as positive.
HER2 status was determined by IHC using the HercepTest, and
score of 0–1+ was regarded as negative (18). A borderline/
equivocal expression of HER-2 was indicated for cerb2 when at
least 10% of tumor cells demonstrated 2+ cytoplasmic membrane
staining, and these samples were confirmed using fluorescence in
situ hybridization with the PathVysion HER2 DNA Probe kit
(Abbott, IL, USA) according to the manufacturer instructions. A
HER2 gene-to-chromosome 17 ratio greater than 2 was consid-
ered positive. The study was approved by the Institutional Review
Board of the Gangnam Severance Hospital and written informed
consent was obtained from the patients.
DNA preparation
DNA was extracted from breast cancer tissues (ER-, PR-, and
HER2-) obtained at the time of surgical resection. Genomic DNA
was extracted using QIAamp DNA extraction kit (Qiagen, Hilden,
Germany) according to the manufacturer protocol. The concen-
tration and quality of genomic DNA was evaluated by Nanodrop
(ND-1000; Thermo Scientific, DE, USA).
Direct sequencing of EGFR, KRAS and TP53 genes
Mutation analysis for EGFR and KRAS genes was performed in
duplicate using direct sequencing and the peptide nucleic acid
(PNA)-mediated PCR clamping method. PCR amplification and
direct sequencing of EGFR gene (exons 18–21), KRAS (exon2) and
TP53 gene (exon 5–9) were performed in 105 TNBCs [22–27].
The primers designed to amplify exons and flanking introns of
those genes are summarized in Table 1. PCR was performed using
an Accu-PowerTM Premix (Bioneer, Daejeon, Korea) under the
following amplification conditions: 94uC for 4 min followed by 50
cycles of 94uC for 1 min, 60uC for 30 s and 72uC for 30 s, and
final extension at 72uC for 15 min. Purified PCR products
obtained using a QIAquick Gel Extraction kit (Qiagen, Du¨sseldorf,
Germany) were used for sequencing with a Big Dye Terminator
Cycle Sequencing Ready Reaction kit (Applied Biosystems, Foster
City, CA, USA). The thermal cycler conditions were as follows:
96uC for 5 min followed by 24 cycles of 96uC for 10 s, 50uC for
5 s and 60uC for 4 min, and final extension at 72uC for 5 min.
The sequences were analysed using ABI 3500Dx system (Applied
Biosystems). Sequences were compared with the database
sequence in GenBank (http://www.ncbi.nlm.nih.gov assessed
June, 2012). The GenBank accession numbers are NM_
005228.3, NM_004985.3 and NC_000017.9 for the EGFR, KRAS
and TP53 genes, respectively.
Mutation analysis of EGFR, KRAS and BRAF genes
We evaluated EGFR and KRAS mutations using the PNA-
ClampTM EGFR and PNAClampTM KRAS Mutation Detection
kits (Panagene, Inc., Daejeon, Korea). PNA-mediated PCR
clamping is a mutant enrichment method and can detect minor
mutant alleles in whole tumor cells [14,28,29]. All reactions were
carried out in a volume of 20ml with template DNA, a primer and
PNA probe set, and SYBR Green PCR master mix according to
the manufacturer instructions. Real-time PCR reaction was
performed using a CFX 96 (Bio-Rad, USA). PCR cycling
conditions were as follows: 5 minutes at 94uC followed by 40
cycles of 94uC for 30 seconds, 70uC for 20 seconds, 63uC for 30
seconds, and then 72uC for 30 seconds. Each kit is designed to
detect 29 mutations in the EGFR gene (exon 18 – 21) and 7
mutations in the KRAS gene (exon 2). Delta Ct values were
calculated for defining whether there were mutations in EGFR and
KRAS [28,29]. BRAFV600E was evaluated using Real-QTMTM
BRAF V600E detection kit (Biossewoom, Inc., Seoul, Korea). All
optical reaction tubes which contained 10 mL genomic DNA and
15 mL RQ-PCR reaction mixture were placed in a CFX96 (Bio-
Rad, USA). The thermal cycler protocol used was 50uC for 120
minutes, 95uC for 10 minutes and then 40 cycles of 95uC for 15
seconds and 58uC for 45 seconds. Data analysis was done
according to the manufacturer instructions.
Copy number analysis of EGFR
EGFR copy number changes in TNBCs were evaluated using
SALSAH MLPAH Probemix P315-B1 EGFR kit (MRC-Holland,
Amsterdam, the Netherlands) that contains 12 reference probes
and 30 probes in the exons of the EGFR gene, including specific
probes for the L858R and T790M mutations. Probe sequences of
SALSAH MLPAH P315-B1 EGFR probemix are available at
http://www.mlpa.com. Denatured DNA samples were hybridized
with probemix for 16 hours at 60uC. Ligation of probes was
performed with the Ligase-65 enzyme at 54uC for 15 min,
followed by 5 minutes at 98uC for heat inactivation of the Ligase-
65 enzyme. PCR was performed with the specific SALSA PCR
primers for 35 cycles (95uC for 30 s, 60uC for 30 s and 72uC for
1 min) using the GeneAmpH PCR System 9700 (Applied
Biosystems, USA). All MLPA analysis of 105 samples was
performed in duplicate. Three cancer cell lines (HCC827,
H2279, and H1975) were used as the positive controls for MLPA
analysis. According to results from fluorescence in situ hybridiza-
tion and/or the nanofluidic digital PCR array, HCC827, H2279
and H1975 were considered to have high-copy number amplifi-
cations, amplifications and single copy gain with L858R and
T790M mutations, respectively [30,31]. To determineanalytical
sensitivity of MLPA for EGFR copy number changes in tumor
cells, DNA from HCC827 was serially diluted with wild type
DNA. Each spiked sample was assayed up to five times using
SALSAHMLPAH Probemix P315-B1 EGFR kit (MRC-Holland).
MLPA fragment analysis data were generated on Applied
Biosystems 3500Dx system (Applied Biosystems). The data were
analyzed using the GeneMarkerH software (SoftGenetics, PA,
USA). The copy number of the EGFR gene was determined on the
basis of the relative peak height ratio of the probes. Seventy-eight
good quality samples (the SD of all 44 probes were within 0.1)
without gain and/or loss were used as a reference group to
construct the mean peak of each probe. The SD of all control
probes in 105 samples, except by random errors due to capillary
electrophoresis conditions (ex. SPG11 gene, 439 nt, 16538-
L21570) and disease-associated control probe (ex.COL11A1 gene,
196 nt, 13232-L14565 etc.) [32], was within 0.1. Based on our
previous report with MLPA copy number detection, we used
thresholds of 1.2 and 0.8 for the detection of single copy gain
(GAIN) and hemizygous deletion (HETD), respectively. Further-
more, the ratios above 2.0 were considered as amplifications
(AMP) and those exceeding 10 as high-copy number amplifica-
tions (HLAMP) [33]. The probe fractions are then divided by the
average probe fraction of the reference group, resulting in a probe
ratio [34].
Statistical Analysis
Patient follow-up periods were calculated as time between
surgery date and the date of last follow-up (months). Relapse free
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survival (RFS) included loco-regional recurrence, distant metasta-
sis, and death from any cause. Breast cancer-specific survival
(BCSS) included only patients who died from any breast cancer-
related cause. TP53 mutations were classified as missense,
nonsense, and frameshift mutations. In addition, missense
mutations were further subdivided as missense mutations in
DNA binding motifs (DBM) and outside the DBM according to
mutation position, nature, and suspected effect on protein
structure and activity [23,35]. Kaplan-Meier survival curves with
log-rank tests were performed to compare RFS and BCSS
according to the type of TP53 mutation. Cox proportional hazard
models were performed to assess the influence of prognostic factors
on RFS. Univariate analyses for age at surgery, tumor size, node
status, Ki67 labeling index and TP53 mutations were performed.
Any factors from the univariate analysis with a p value less than
0.10 was included in the multivariate analysis. All statistical
analyses were performed using SPSS 20.0 (SPSS Inc, Chicago, IL,
USA). For all statistical analyses except the univariate analysis, a p
value less than 0.05 was regarded significant.
Results
Patient characteristics
The clinicopathological characteristics of TNBCs are listed in
Table 2. The median age of patients was 49 years old (range, 28–
76) and the median tumor size was 22 mm (range, 5–100 mm).
The majority of TNBCs (84/105, 78.5%) were invasive ductal
carcinomas with nuclear grade 2–3 and histologic grade II-III. Of
105 TNBCs, 33 (31.4%) carried mutations in exon 5–9 of the
TP53. Sixteen (48.5%) carried a missense mutation, and 17
(51.5%) harbored a frameshift, nonsense, or splicing mutation.
Mutation analysis of EGFR, KRAS, BRAF and TP53 genes
The mutation frequency of KRAS and EGFR gene were 1.9%
(2/105) and 1.0% (1/105), respectively. One activating mutation
(exon 19 del) was detected using PNA-mediated clamping PCR in
a commonly deleted region (codons 746–753) of the EGFR gene.
Two KRAS mutations (G12V and G12D) were identified using
PNA-mediated clamping PCR and sequencing. There was no
BRAFV600E mutation found (Table 3 & Table S1).
Frequencies and spectrum of EGFR gene copy number
changes
The frequency of EGFR copy number changes was noted in
15.2% of total 105 TNBCs. Among them, increased or decreased
EGFR copy number was detected in 13 (12.4%) and 3 cases
Table 1. PCR primers of TP53 and EGFR gene.
Target Exon Forward Primer (5’ 3’) Reverse Primer (5’ 3’) PCR product size (bps)
EGFR 18 ATGTCTGGCACTGCTTTCCA ACAGCTTGCAAGGACTCTGG 277
19 AGATCACTGGGCAGCATGT AGCAGCTGCCAGACATGAG 246
20 CATTCATGCGTCTTCACCTG CATATCCCCATGGCAAACTC 377
21 AGCCATAAGTCCTCGACGTG ATCCTCCCCTGCATGTGTTA 372
KRAS 2 TGTATTAACCTTATGTGTGACA CTTGTAATAAGTACTCATGAAA 279
TP53 5&6 CACTTGTGCCCTGACTTTCA TTGCACATCTCATGGGGTTA 619
7 CCTGCTTGCCACAGGTCT TGATGAGAGGTGGATGGGTAG 279
8&9 CAAGGGTGGTTGGGAGTAGA CCCCAATTGCAGGTAAAACA 496
Abbreviations: bps, base pairs; PCR, polymerase chain reaction.
doi:10.1371/journal.pone.0079014.t001
Table 2. Clinicopathological Characteristics of Triple Negative
Breast Cancers (n = 105).
Numbers Percentage (%)
Age (years)
Median/Range 49/28–76
Tumor size
Median/Range 22 mm/5–100 mm
,20 mm/$20 mm 41/64 39.0/61.0
Histolopathological features
Invasive ductal carcinoma 88 83.8
Medullary carcinoma 5 4.8
Invasive lobular carcinoma 2 1.9
Metaplastic carcinoma 2 1.9
Specialized typesa 8 7.6
T stage
1/2/3/4/ 43/57/2/3/ 41/54.3/1.9/2.9
N stage
01/2/3 65/28/7/5 61.9/26.7/6.7/4.7
Nuclear gradeb
1/2/3 2/28/70 1.9/26.7/66.7
Histologic gradec
I/II/III 7/25/68 6.7/23.8/64.8
Ki67 labeling index
,5% 17 16.2
5% ,49% 67 63.8
$50% 21 20
TP53 gene mutations
Missense DBM 11 10.5
Missense non-DBM 5 4.8
Frameshift 8 7.6
Nonsense 7 6.7
Splicing 2 1.9
aAdenoid cystic carcinoma, ductal carcinoma in situ, invasive cribriform
carcinoma, invasive micropapillary carcinoma, invasive tubular carcinoma,
neuroendocrine carcinoma and mucinous carcinoma. b,c Five samples did not
have a defined histologic grade and nuclear grade.
doi:10.1371/journal.pone.0079014.t002
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Table 3. Molecular Characteristics of Triple Negative Breast Cancers (n = 105).
Number of cases (%) EGFR copy number change EGFR mutation KRAS mutation TP53 mutation
61 (58.1%) N 2 2 2
25 (23.8%) N 2 2 +
2 (1.9%) N 2 +a +
1 (1.0%) N +b 2 2
6 (5.7%) I 2 2 2
5 (4.8%) I 2 2 +
2 (1.9%) I{ 2 2 2
2 (1.9%) D 2 2 2
1 (1.0%) D 2 2 +
105 1 (1.0%) 2 (1.9%) 33 (31.4%)
’2’, wild type; ’+’, mutant type; ’D’, decreased copy number (hemizygous deletion); ‘N’, normal copy number; ’I’, increased EGFR copy number (single copy gain,
amplification and high-copy number amplification); { single exon amplification; a p.Gly12Val and p.Gly12Asp; b Deletion on Exon 19. BRAF gene mutation was not
detected in all cases
doi:10.1371/journal.pone.0079014.t003
Figure 1. Examples of representative scatter plot patterns of multiplex ligation-dependent probe amplification (MLPA) analysis for
the EGFR gene. Gain or loss (peak ratio cut off,,0.8 or.1.2) of exons in EGFR gene were represented by red squares. Green square indicated within
neutral peak ratio of EGFR gene. Three white squares indicate specific probe for Y chromosome (105 bps), the L858R (281 bps) and the T790M
mutations (246 bps). Blue squares represent control probes. ‘HETD’, hemizygous deletion; ‘GAIN’, copy gain; ‘AMP’, amplifications; ‘HLAMP’, high-
copy amplifications.
doi:10.1371/journal.pone.0079014.g001
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(2.9%), respectively. Of 13 cases, two cases (1.9%) showed an
increased copy number of a single exon (one in exon 1 and the
other in exon 21) and 11 cases (10.5%) showed increased copy
number changes consists of five single copy gain (GAIN) (4.8%),
two amplification (AMP) (1.9%) and four high-copy number
amplification (HLAMP) cases (3.8%) (Figure 1 & Table 3).
Association between TP53 mutations and prognosis in
105 TNBC patients
Of 105 TNBC patients with a median follow up period of 35
months, there were 20 (19.0%) cases of breast cancer relapse, and
8 cases (7.6%) were due to breast cancer-related death. Kaplan-
Meier survival analysis of TNBC patients grouped according to
the type of TP53 mutation showed that missense mutations in
DBM (P=0.036) and non-DBM (P=0.011) were associated with a
higher relapse rate compared with patients without the mutations,
whereas other types of mutations including frameshift, nonsense,
and splicing mutations (P=0.462) was not significant. The relapse
incidence per 100 persons at 25 months for non-mutations, DBM
mutations and non-DBM missense mutation groups were 8, 30,
40, respectively (Figure 2A). The DBM mutations (P=0.311), non-
DBM missense mutation (P=0.449) and other mutations
(P=0.274) were not significantly associated with BCSS compared
with wild type (figure 2B). Prognostic factors associated with
relapse free survival in the univariate analysis had higher T and N
stage and TP53 mutation status. However, in the multivariate
analysis, only N stage with grade 2 or 3 was associated with relapse
rate (Table 4).
Sensitivity analysis of EGFR MLPA
Detection of the EGFR amplifications in HCC827 cell line was
possible in spiked samples containing 6.25% of HCC827 DNA
(Table 5). All five replicates of spiked samples with 6.25% of
HCC827 DNA showed EGFR amplifications.
Discussion
Recently, oncogenic mutations linked to the AKT and MEK/
MAPK pathways have been evaluated as possible predictive
markers associated with a good response to EGFR-targeted agents
in TNBCs [15,17,18,36]. Grob et. al., have reported that no
mutation was found in EGFR, KRAS, and BRAF among 63
TNBCs, and only one EGFR amplification case was detected [15],
consistent with other results in European patients [16,17].
However, mutations and copy number changes of the EGFR gene
were more frequently observed in Asian patients with a detection
rate up to 11.4% [18] and 21% [19], respectively. Out of all 105
TNBCs, 10.5% showed increased EGFR copy number changes
including five GAIN, four HLAMP, two AMP, and one case
Figure 2. Kaplan-Meier relapse free survival (RFS) and breast cancer specific survival (BCSS) curves of patients with triple negative
breast cancer. (a) RFS and (b) BCSS curves stratified by non-mutations, missense mutations in the DBM, missense mutations outside the DBMs and
others including nonsense, frameshift and splicing mutations in the TP53 gene.
doi:10.1371/journal.pone.0079014.g002
Table 4. Univariate and Multivariate analysis of Relapse Free
Survival in 105 TNBCs.
Univariate Multivariate
HR 95% CI of HR P HR 95% CI of HR P
T status
T#1 1 1
T$3 6.118 1.381–27.109 0.017 3.648 0.789–16.868 0.098
N status
N#1 1 1
N$2 4.16 1.481–11.687 0.007 2.945 1.010–8.588 0.048
TP53 mutations
Wild type 1 1
Mutations 2.742 1.080–6.960 0.034 2.193 0.852–5.643 0.104
HR, hazard ratio.
doi:10.1371/journal.pone.0079014.t004
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harbored activating mutation (exon 19 del). These genetic
aberrations were thought to be susceptible to either EGFR-TKIs
or EGFR-blocking monoclonal antibody therapy in primary non–
small cell lung cancer [9–12] or in recurrent glioblastoma [13].
The frequency of activating EGFR mutations in our study was
lower than that of a recent Asian study among patients in
Singapore (8/70). However, the frequencies of activating EGFR
mutations and copy number changes in our study were
comparable to that of a study including Caucasian patients [20],
which reported four HLAMP cases (6.2% 4/65) and one EGFR
gene mutation case (1.5%, 1/65).
In a total of 105 TNBCs, two KRAS point mutations and three
HETD cases were detected (4.8%, 5/105). Mutations of the KRAS
gene are known to be negative predictive genetic markers for
EGFR targeted therapy and were significantly associated with
resistance to EGFR-blocking monoclonal antibody (cetuximab) in
colon cancer [27,37]. In our study, three HETD cases were
detected, but a partial deletion variant of EGFR gene, EGFRvIII
(in-frame deletion of exon 2–7) reported frequently in glioblastoma
[13,38] and breast cancer [39], was not observed. Two cases
showed only single exon copy number amplifications. Tang et al.
showed that EGFRvIII enhanced the tumorigenic potential of
breast cancer cells in mice [40] and Sok et al. also showed that
xenografts expressing EGFRvIII grew more rapidly than tumors
derived from vector-transfected control cells [38]. However, the
functions of the whole gene deletion of EGFR or the single exon
copy number amplifications in tumor cells were not evaluated.
Therefore, further investigation is needed to characterize the
functional and clinical significance of the whole gene deletion of
EGFR and the single exon copy number changes.
TP53 mutations were more prevalently detected in tumors with
high grade, large size, and node-positivity. The relative risk of
deaths with TP53 mutations was 2 to 3 times higher than those
without TP53 mutations, especially for the group with missense
mutation in DBM was associated with shortest survival [23]. In
our study, patients with missense mutations showed reduction in
relapse free survival, but the effect of the missense mutation in the
DBM was not stronger than the missense mutation outside the
DBM on breast cancer relapse.
Among 105 TNBCs, 5 of 12 tumors with increased EGFR copy
number or EGFR mutation also had TP53 mutations (Table3 &
Table S1). Several studies have reported that amplification of EGFR
and inactivation of TP53 are associated with sensitivity to anti-EGFR
monoclonal antibodies in metastatic colorectal cancer [41,42].
However, in TNBCs, the TP53 mutation has been limited as one
prognostic marker that can identify tumors with more aggressive
behavior [43,44]. Therefore, it is necessary to further evaluate the
correlation between TP53 mutation and sensitivity of anti-EGFR
therapy in TNBCs with EGFR amplification or EGFR mutation.
The frequency of TNBCs varies by race. In African Americans,
up to 55% of breast cancers were TNBCs, which was 2–3 times
more frequent than in other racial groups [2,5]. Among Asian
populations, TNBCs account for 8.0 to 24.1% of all breast cancers
(24.1% in Korean patients; 18.6% in Chinese patients; 8% in
Japanese patients) [3,4,6]. Copy number changes of the EGFR
gene were detected in 6.2% (in Western patients) to 21% (in Asian
patients) of TNBCs [19,20].
Several randomized clinical studies of anti-EGFR therapy reported
that fewer than 20% of metastatic TNBCs showed response to anti-
EGFR therapy [45,46] and the use of these therapies for targeted
breast cancer treatment has been controversial. However, these
studies had not clearly validated the genetic predictive markers that
can modulate sensitivity or resistance to anti-EGFR therapy as
described in other cancers [9–13,47].
According to previous studies, TKIs may be more promising in
specific subsets of patients with activating EGFR mutations,
whereas EGFR-blocking monoclonal antibodies may be more
effective in TNBC cases where the whole EGFR gene copy number
is increased [47,48]. Therefore, analysis of EGFR mutations and
copy number changes could offer new therapeutic options for
TNBC patients. Moreover, analysis of EGFR mutations and copy
number changes may be more beneficial in the racial groups with
high frequencies of TNBCs and with EGFR gene aberrations.
This study provides the spectrum of copy number changes and
mutation statuses of the EGFR gene in Korean TNBC patients.
Future studies should include evaluation of clinical outcomes of
TNBC patients who undergo anti-EGFR therapy according to the
genetic status of EGFR.
Supporting Information
Table S1 Forty-four TNBCs with Abnormal Status of EGFR,
KRAS or/and TP53.
(DOCX)
Acknowledgments
We gratefully acknowledge Dr. Mitsuo Sato (Nagoya University Graduate
School of Medicine, Japan) and Dr. Sun-Young Kong (National Cancer
Center, Korea) for the supply of adenocarcinoma line HCC827, H1975
and H2279.
Author Contributions
Conceived and designed the experiments: KAL YK JK. Performed the
experiments: YK JJ HDL. Analyzed the data: KAL YK JK. Contributed
reagents/materials/analysis tools: KAL YK JK WL. Wrote the paper:
KAL YK JK.
References
1. Reis-Filho JS, Tutt AN (2008) Triple negative tumours: a critical review.
Histopathology 52: 108–118.
2. Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, et al. (2009)
Population differences in breast cancer: survey in indigenous African women
Table 5. Analytical Sensitivity of MLPA for EGFR copy number
changes in the HCC827 cell line.
Concentrations of
HCC827 (%)a Number of replicates MLPA
100 3 +b
50 3 +
25 5 +
12.5 5 +
6.25 5 +
3.13 3 –
Wild type DNA 3 –
MLPA, multiplex ligation-dependent probe amplification. aDNA of the HCC827
was serially diluted with wild type DNA. b All spiked samples analyzed using
MLPA three or five times, and all replicates with from 100% to 6.25% of HCC827
DNA showed EGFR amplifications.
doi:10.1371/journal.pone.0079014.t005
Spectrum of EGFR Gene Copy Number Changes in TNBCs
PLOS ONE | www.plosone.org 6 October 2013 | Volume 8 | Issue 10 | e79014
reveals over-representation of triple-negative breast cancer. J Clin Oncol 27:
4515–4521.
3. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, et al. (2006) Clinicopathologic
significance of the basal-like subtype of breast cancer: a comparison with
hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 37:
1217–1226.
4. Kurebayashi J, Moriya T, Ishida T, Hirakawa H, Kurosumi M, et al. (2007) The
prevalence of intrinsic subtypes and prognosis in breast cancer patients of
different races. Breast 16 Suppl 2: S72–77.
5. Stead LA, Lash TL, Sobieraj JE, Chi DD, Westrup JL, et al. (2009) Triple-
negative breast cancers are increased in black women regardless of age or body
mass index. Breast Cancer Res 11: R18.
6. Yin WJ, Lu JS, Di GH, Lin YP, Zhou LH, et al. (2009) Clinicopathological
features of the triple-negative tumors in Chinese breast cancer patients. Breast
Cancer Res Treat 115: 325–333.
7. Carey L, Winer E, Viale G, Cameron D, Gianni L (2010) Triple-negative breast
cancer: disease entity or title of convenience? Nat Rev Clin Oncol 7: 683–692.
8. Hudis CA, Gianni L (2011) Triple-negative breast cancer: an unmet medical
need. Oncologist 16 Suppl 1: 1–11.
9. Fukui T, Mitsudomi T (2008) Mutations in the epidermal growth factor receptor
gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers. Gen
Thorac Cardiovasc Surg 56: 97–103.
10. Sequist LV, Bell DW, Lynch TJ, Haber DA (2007) Molecular predictors of
response to epidermal growth factor receptor antagonists in non-small-cell lung
cancer. J Clin Oncol 25: 587–595.
11. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations
in lung cancer: correlation with clinical response to gefitinib therapy. Science
304: 1497–1500.
12. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004)
Activating mutations in the epidermal growth factor receptor underlying
responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:
2129–2139.
13. Lv S, Teugels E, Sadones J, De Brakeleer S, Duerinck J, et al. (2012) Correlation
of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent
glioblastoma treated in a phase II clinical trial with the EGFR-blocking
monoclonal antibody cetuximab. Int J Oncol.
14. Araki T, Shimizu K, Nakamura T, Baba M, Kawai Y, et al. (2011) Clinical
screening assay for EGFR exon 19 mutations using PNA-clamp smart
amplification process version 2 in lung adenocarcinoma. Oncol Rep 26:
1213–1219.
15. Grob TJ, Heilenkotter U, Geist S, Paluchowski P, Wilke C, et al. (2012) Rare
oncogenic mutations of predictive markers for targeted therapy in triple-negative
breast cancer. Breast Cancer Res Treat 134: 561–567.
16. Sanchez-Munoz A, Gallego E, de Luque V, Perez-Rivas LG, Vicioso L, et al.
(2010) Lack of evidence for KRAS oncogenic mutations in triple-negative breast
cancer. BMC Cancer 10: 136.
17. Jacot W, Lopez-Crapez E, Thezenas S, Senal R, Fina F, et al. (2011) Lack of
EGFR-activating mutations in European patients with triple-negative breast
cancer could emphasise geographic and ethnic variations in breast cancer
mutation profiles. Breast Cancer Res 13: R133.
18. Teng YH, Tan WJ, Thike AA, Cheok PY, Tse GM, et al. (2011) Mutations in
the epidermal growth factor receptor (EGFR) gene in triple negative breast
cancer: possible implications for targeted therapy. Breast Cancer Res 13: R35.
19. Toyama T, Yamashita H, Kondo N, Okuda K, Takahashi S, et al. (2008)
Frequently increased epidermal growth factor receptor (EGFR) copy numbers
and decreased BRCA1 mRNA expression in Japanese triple-negative breast
cancers. BMC Cancer 8: 309.
20. Shah SP, Roth A, Goya R, Oloumi A, Ha G, et al. (2012) The clonal and
mutational evolution spectrum of primary triple-negative breast cancers. Nature
486: 395–399.
21. Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status
by immunohistochemistry is superior to the ligand-binding assay for predicting
response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17: 1474–
1481.
22. Mitsudomi T, Yatabe Y (2010) Epidermal growth factor receptor in relation to
tumor development: EGFR gene and cancer. FEBS J 277: 301–308.
23. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, et al. (2006) The clinical
value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin
Cancer Res 12: 1157–1167.
24. Olivier M, Hainaut P (2001) TP53 mutation patterns in breast cancers:
searching for clues of environmental carcinogenesis. Semin Cancer Biol 11: 353–
360.
25. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, et al. (2009)
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.
Nat Rev Clin Oncol 6: 519–527.
26. Langer CJ (2011) Roles of EGFR and KRAS Mutations in the Treatment Of
Patients With Non-Small-Cell Lung Cancer. P T 36: 263–279.
27. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, et al. (2007)
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer
treated by Cetuximab plus chemotherapy. Br J Cancer 96: 1166–1169.
28. Kwon MJ, Lee SE, Kang SY, Choi YL (2011) Frequency of KRAS, BRAF, and
PIK3CA mutations in advanced colorectal cancers: Comparison of peptide
nucleic acid-mediated PCR clamping and direct sequencing in formalin-fixed,
paraffin-embedded tissue. Pathol Res Pract 207: 762–768.
29. Han HS, Lim SN, An JY, Lee KM, Choe KH, et al. (2012) Detection of EGFR
mutation status in lung adenocarcinoma specimens with different proportions of
tumor cells using two methods of differential sensitivity. J Thorac Oncol 7: 355–
364.
30. Wang J, Ramakrishnan R, Tang Z, Fan W, Kluge A, et al. (2010) Quantifying
EGFR alterations in the lung cancer genome with nanofluidic digital PCR
arrays. Clin Chem 56: 623–632.
31. Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, et al. (2006)
Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines
correlates with gene copy number and EGFR mutations but not EGFR protein
levels. Clin Cancer Res 12: 7117–7125.
32. Vargas AC, Reed AE, Waddell N, Lane A, Reid LE, et al. (2012) Gene
expression profiling of tumour epithelial and stromal compartments during
breast cancer progression. Breast Cancer Res Treat.
33. Jeuken J, Cornelissen S, Boots-Sprenger S, Gijsen S, Wesseling P (2006)
Multiplex ligation-dependent probe amplification: a diagnostic tool for
simultaneous identification of different genetic markers in glial tumors. J Mol
Diagn 8: 433–443.
34. Jeuken J, Sijben A, Alenda C, Rijntjes J, Dekkers M, et al. (2009) Robust
detection of EGFR copy number changes and EGFR variant III: technical
aspects and relevance for glioma diagnostics. Brain Pathol 19: 661–671.
35. Cho Y, Gorina S, Jeffrey PD, Pavletich NP (1994) Crystal structure of a p53
tumor suppressor-DNA complex: understanding tumorigenic mutations. Science
265: 346–355.
36. Nakajima H, Ishikawa Y, Furuya M, Sano T, Ohno Y, et al. (2012) Protein
expression, gene amplification, and mutational analysis of EGFR in triple-
negative breast cancer. Breast Cancer.
37. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, et al. (2006) KRAS
mutation status is predictive of response to cetuximab therapy in colorectal
cancer. Cancer Res 66: 3992–3995.
38. Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, et al. (2006) Mutant
epidermal growth factor receptor (EGFRvIII) contributes to head and neck
cancer growth and resistance to EGFR targeting. Clin Cancer Res 12: 5064–
5073.
39. Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, et al.
(1995) Frequent expression of a mutant epidermal growth factor receptor in
multiple human tumors. Cancer Res 55: 5536–5539.
40. Tang CK, Gong XQ, Moscatello DK, Wong AJ, Lippman ME (2000)
Epidermal growth factor receptor vIII enhances tumorigenicity in human breast
cancer. Cancer Res 60: 3081–3087.
41. Di Fiore F, Sesboue R, Michel P, Sabourin JC, Frebourg T (2010) Molecular
determinants of anti-EGFR sensitivity and resistance in metastatic colorectal
cancer. Br J Cancer 103: 1765–1772.
42. Oden-Gangloff A, Di Fiore F, Bibeau F, Lamy A, Bougeard G, et al. (2009)
TP53 mutations predict disease control in metastatic colorectal cancer treated
with cetuximab-based chemotherapy. Br J Cancer 100: 1330–1335.
43. Powell B, Soong R, Iacopetta B, Seshadri R, Smith DR (2000) Prognostic
significance of mutations to different structural and functional regions of the p53
gene in breast cancer. Clin Cancer Res 6: 443–451.
44. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, et al. (2007)
Prognostic markers in triple-negative breast cancer. Cancer 109: 25–32.
45. Dickler MN, Cobleigh MA, Miller KD, Klein PM, Winer EP (2009) Efficacy
and safety of erlotinib in patients with locally advanced or metastatic breast
cancer. Breast Cancer Res Treat 115: 115–121.
46. Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, et al. (2012) TBCRC
001: Randomized Phase II Study of Cetuximab in Combination With
Carboplatin in Stage IV Triple-Negative Breast Cancer. J Clin Oncol.
47. Brand TM, Iida M, Wheeler DL (2011) Molecular mechanisms of resistance to
the EGFR monoclonal antibody cetuximab. Cancer Biol Ther 11: 777–792.
48. Moran T, Sequist LV (2012) Timing of Epidermal Growth Factor Receptor
Tyrosine Kinase Inhibitor Therapy in Patients With Lung Cancer With EGFR
Mutations. J Clin Oncol.
Spectrum of EGFR Gene Copy Number Changes in TNBCs
PLOS ONE | www.plosone.org 7 October 2013 | Volume 8 | Issue 10 | e79014
